MADISON (WKOW) -- A Madison company is teaming up with a national biotechnology company to manufacture a vaccine for COVID-19.
Waisman Biomanufacturing at UW-Madison is partnering with North Carolina-based Heat Biologics to produce a vaccine for phase one and phase two clinical trials the university announced Monday morning.
According to UW-Madison officials, the vaccine will target those most vulnerable to COVID-19, including the elderly and those with health conditions that weaken their immune system. It will also target those with heart conditions, severe obesity, diabetes, chronic kidney disease, and liver disease.
"In addition to its potential as a standalone COVID-19 vaccine, we believe this platform holds enormous promise in combination with other vaccines under development and in clinical trials by boosting the patient's T-cell immunity," Jeff Wolf, CEO of Heat Biologics said.
The vaccine will enable long-term cellular immunity by teaching the T-cells to recognize and fight off the pathogen in the future and fight off infection.
"Waisman Biomanufacturing's mission is to advance novel vaccines and therapeutics into early human clinical trials," Carl Ross, managing director of Waisman Biomanufacturing said.
"We are very excited to be able to offer what we have to this cause," Ross said.
Waisman Biomanufacturing, which is part of the Waisman Center, has worked on other vaccine projects for infectious diseases such as Ebola, influenza, and malaria.
Phase one trials could begin in early 2021, and UW-Madison may be a trial site, according to Monday's news release.